Evidence map›Paper›PMID 34812311›Full record

ArticleCureus2021

Incidence and Outcome of Acute Kidney Injury in Patients Hospitalized With Coronavirus Disease-19 at a Tertiary Care Medical Center in Saudi Arabia.

Mahfooz A Farooqui, Alwaleed Almegren, Sattam R Binrushud, Faisal A Alnuwaiser, Nasser M Almegren, Nawaf A Alhamied, Eissa A Aloraifi, Abdullah M Alothman, Moath A Aldafas, Husam I Ardah and 1 more

Abstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. The Nephroprotective Activity ofJournal of experimental pharmacology · 2024
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mahfooz A FarooquiDivision of Nephrology, Department of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City Riyadh, Riyadh, SAU.
Alwaleed AlmegrenDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Sattam R BinrushudDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Faisal A AlnuwaiserDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Nasser M AlmegrenDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Nawaf A AlhamiedDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Eissa A AloraifiDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Abdullah M AlothmanDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Moath A AldafasDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Pharmacy, Riyadh, SAU.
Husam I ArdahDepartment of Biostatistics and Epidemiology, King Abdullah International Medical Research Center, Riyadh, SAU.
Fayez F AlhejailiDepartment of Nephrology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction The systemic acute respiratory syndrome coronavirus (SARS-CoV-2) has been associated with acute kidney injury (AKI). We retrospectively studied the incidence and outcome of AKI in patients hospitalized with COVID-19 at King Abdulaziz Medical City (KAMC) Riyadh, Kingdom of Saudi Arabia. Methods A retrospective cohort study was conducted after ethical approval from the institutional review board of King Abdullah International Medical Research Center (KAIMRC). Subjects were identified by Data Management Office of KAIMRC. The data were extracted from electronic medical records using a customized data collection sheet. The study included all adult patients (>18 years) who tested positive for COVID-19 by polymerase chain reaction and were admitted at KAMC from March 2020 until the end of September 2020. Patients with a history of end-stage kidney diseases and patients where adequate data were not available to establish diagnosis of AKI were excluded. Patient demographics, comorbid conditions, medications, use of mechanical ventilation, and 30-day mortality were recorded. Results During the study period (01 March 2020 to 30 September 2020) 1293 patients were hospitalized at KAMC with the diagnosis of COVID-19. After excluding the patients who met the exclusion criteria, data were collected for 1025 patients [male 582 (56.8%); female 443 (43.2%)]. On univariate analysis, increasing age, male gender, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and vasopressors, presence of chronic kidney disease, coronary artery disease, chronic obstructive pulmonary disease, dyslipidemia, diabetes mellitus, heart failure, and hypertension, kidney transplant status, and mechanical ventilation were associated with development of AKI. On multivariate logistic regression analysis, independent predictors of AKI were restricted to increasing age, presence of chronic kidney disease, hypertension, kidney transplant status, use of vasopressors, and mechanical ventilation. For patients who developed AKI, 30-day mortality was 40.7% compared to 3.7% for those who did not develop AKI (p<0.001). Conclusion For hospitalized patients with COVID-19, we observed an incidence of AKI of 36%. Increasing age, presence of chronic kidney disease and hypertension, kidney transplant status, use of vasopressors, and mechanical ventilation were independently associated with development of AKI. Presence of AKI was associated with higher 30-day mortality (40.7% vs 3.7%).

Indexed as

30 day mortalityacute kidney injurycovid-19hospitalizedsars-cov-2

Identifiers

PMID34812311
PMCPMC8604091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.